FDA nod to UCB’s Vimpat as an add-on therapy for epilepsy
The U.S. Food and Drug Administration has given the approval to UCB’s Vimpat® (lacosamide) for use as an adjunct therapy in the treatment of partial-onset seizures in epilepsy patients older than 17 years of age. The novel anti-epileptic drug has an innovative mechanism of action which involves the modulation of activity of sodium channels in the nervous system. It prolongs the long-lasting resting condition of the channel, thereby controlling the hyperactive nerve cells.

The European Commission has granted orphan drug designation to Cethrin developed by
The U.S. Food and Drug Administration has approved 